Latest news with #www.sedarplus.ca
Cision Canada
3 days ago
- Business
- Cision Canada
LSL PHARMA GROUP SECURES $17.5 MILLION FROM DESJARDINS AND BDC
BOUCHERVILLE, QC, June 27, 2025 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL) (" LSL Pharma" or the " Corporation"), a Canadian integrated pharmaceutical company, today announced having secured a new $7.5 million operating line of credit (the "New Line of Credit") from Caisse Populaire Desjardins des Patriotes ("Desjardins") as well as new $10 million pari-passu term loan from BDC and Caisse Populaire Desjardins (the "Term Loan"). The New Line of Credit which is now available, represents a $4.2 million increase over the prior combined line of credit from TD Bank and Scotia Bank. The Term Loan financing expected to close on or about July 7, 2025 will be disbursed in three separate tranches. The first tranche to be disbursed on closing and serve to reimburse existing loans totalling $3.2 million plus accrued interest, as well as all outstanding Convertible Debentures listed asTSXV: representing a principal amount of $3.288 million plus accrued interest (the "Redemption"). The Redemption will be subject to TSXV approval and a formal announcement and notice to Debenture holders, as per the terms of the Debenture Indenture dated November 1, 2023, which is available under LSL Pharma's issuer profile on The second and third tranches will be used to fund capital expenditures and serve to reimburse other debts and loans. Disbursement of the second and third tranches is subject to certain conditions and is expected to be made available before the end of the current fiscal year. The New loan once fully disbursed, will help reduce the Corporation's annual debt servicing requirements and contribute to lower the Corporation's overall interest costs. Interest rate on the New Line of Credit as well as the Desjardins portion of the Term Loan will be based on Desjardins' prime rate plus 1%, which may be reduced based on financial criteria. The BDC portion of the Term Loan will be BDC's base rate plus 2.0% (the "Rate"). The Rate may be reduced by up to 2.5% should LSL Pharma meet certain financial criteria. The various portions of the New Loan will be amortized over 8 to 20 years, include a capital repayment moratorium for the first year on the BDC portion and will be subject to nominal financial covenants. "We are pleased to announce this New Financing and thank Desjardins and BDC for supporting LSL Pharma and sharing our vision, as we keep implementing organic and strategic growth initiatives" said Francois Roberge, President and Chief Executive Officer. "The New Line of Credit and Term loan will significantly increase our working capital flexibility by providing us with in excess of $6 million of additional financing not allocated to loans/debt repayments", said Luc Mainville, Executive Vice-President and Chief Financial Officer. Caution regarding forward-looking statements This press release may contain forward-looking statements as defined under applicable Canadian securities legislation. Forward-looking statements can generally be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "continue" or similar expressions. Forward-looking statements are based on a number of assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Corporation's ability to control or predict, that could cause actual results or performance to differ materially from those expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, those identified in the Corporation's filings with Canadian securities regulatory authorities, such as legislative or regulatory developments, increased competition, technological change and general economic conditions. All forward-looking statements made herein should be read in conjunction with such documents. Readers are cautioned not to place undue reliance on forward-looking statements. No assurance can be given that any of the events referred to in the forward-looking statements will transpire, and if any of them do, the actual results, performance or achievements of the Corporation may differ materially from those expressed or implied by the forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. The Corporation does not undertake to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) have reviewed or accept responsibility for the adequacy or accuracy of this release. About LSL Pharma Group Inc. LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company specializing in the development, manufacturing and commercialization of high-quality sterile ophthalmic pharmaceutical products, as well as pharmaceutical, cosmetic and natural health products in solid, semi-solid and liquid dosage forms. Companies forming part of LSL Pharma Group are Steri-Med Pharma Inc., LSL Laboratory Inc., Virage Santé Inc. and Dermolab Pharma Ltd. For further information, please visit our website at SOURCE Groupe LSL PHARMA INC.
Cision Canada
3 days ago
- Business
- Cision Canada
MERCER PARK OPPORTUNITIES CORP. ANNOUNCES FILING OF ANNUAL INFORMATION FORM AND INVESTOR CONFERENCE CALL
TORONTO, June 26, 2025 /CNW/ - Mercer Park Opportunities Corp. (TSX: SPAC.U) (TSX: and (TSX: ("Mercer" or the "Corporation") filed its annual information form on the System for Electronic Document Analysis and Retrieval Plus ("SEDAR+") and may be viewed by interested parties under the Corporation's profile at The Corporation would also like to provide a brief update on the status of its qualifying acquisition. The Corporation is currently in the process of identifying specific target business(es) with which to pursue a qualifying acquisition but has not entered into any definitive agreement with respect to a qualifying acquisition as of the date hereof. Consistent with its IPO prospectus, the Corporation is considering potential targets in a few different industries and business sectors, including cannabis, for its qualifying acquisition. Senior management will be hosting an investor conference call to provide a business update and allow holders of Class A restricted voting shares the opportunity to hear from and ask questions of management. The call will be hosted by: Jonathan Sandelman, Chief Executive Officer, Chairman and Director and Joshua Snyder, Head of Mergers & Acquisitions. Conference Call Details: Please call in at least 10 minutes prior to the call. Date: July 2, 2025, at 10:00 a.m. (Eastern Time) Dial-in Number: 203-626-2883 About Mercer Park Opportunities Corp. Mercer Park Opportunities Corp. is a special purpose acquisition corporation incorporated under the laws of the Cayman Islands for the purpose of effecting a qualifying acquisition. The Corporation's registered and head offices are both located at the offices of CO Services Cayman Limited, Willow House, Cricket Square, Grand Cayman KY1 1001, Cayman Islands. About Mercer Park III, L.P. Mercer Park III, L.P. is a limited partnership formed under the laws of Delaware that is indirectly controlled by Jonathan Sandelman. Forward-Looking Statements This press release may contain forward-looking information within the meaning of applicable securities legislation, which reflects the Corporation's and Mercer Park III L.P.'s current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the control of the Corporation and Mercer Park III, L.P., that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to, intentions related to the Corporation's qualifying acquisition and related transactions, and the factors discussed under "Risk Factors" in the annual information form dated June 26, 2025 and the prospectus dated July 16, 2024. Neither Corporation nor Mercer Park III, L.P. undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. SOURCE Mercer Park Opportunities Corp.
Cision Canada
3 days ago
- Business
- Cision Canada
Neo Announces Voting Results from Annual General Meeting of Shareholders
TORONTO, June 26, 2025 /CNW/ - Neo Performance Materials Inc. (" Neo" or the " Company") (TSX: NEO) reports, in accordance with the policies of the Toronto Stock Exchange, the results of the matters put before shareholders for consideration and approving at the Company's annual general meeting of shareholders, as described in the management information circular dated May 21, 2025 are set out below. A total of 25.6 million common shares were voted in person or by proxy, representing 61.2% of the outstanding common shares. Shareholders voted as follows: Cautionary Statements Regarding Forward Looking Statements This news release contains "forward-looking information" within the meaning of applicable securities laws in Canada. Forward-looking information may relate to future events or future performance of Neo. All statements in this news release, other than statements of historical facts, with respect to Neo's objectives and goals, as well as statements with respect to its beliefs, plans, objectives, expectations, anticipations, estimates, and intentions are forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "continues", "forecasts", "projects", "predicts", "intends", "anticipates" or "believes", or variations of, or the negatives of, such words and phrases, or state that certain actions, events or results "may", "could", "would", "should", "might" or "will" be taken, occur or be achieved. This information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. Neo believes the expectations reflected in such forward-looking information are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking information included in this discussion and analysis should not be unduly relied upon. For more information on Neo, investors should review Neo's continuous disclosure filings available under its profile at Information contained in forward-looking statements in this press release is provided as of the date hereof and Neo disclaims any obligation to update any forward-looking information, whether as a result of new information or future events or results, except to the extent required by applicable securities laws. About Neo Performance Materials Neo manufactures the building blocks of many modern technologies that enhance efficiency and sustainability. Neo's advanced industrial materials – magnetic powders, rare earth magnets, magnetic assemblies, specialty chemicals, metals, and alloys – are critical to the performance of many everyday products and emerging technologies. Neo's products fast-forward technologies for the net-zero transition. The business of Neo is organized along three segments: Magnequench, Chemicals & Oxides and Rare Metals. Neo is headquartered in Toronto, Ontario, Canada; with corporate offices in Greenwood Village, Colorado, United States; Singapore; and Beijing, China. Neo has a global platform that includes manufacturing facilities located in China, Germany, Canada, Estonia, Thailand and the United Kingdom, as well as one dedicated research and development centre in Singapore. For more information, please visit SOURCE Neo Performance Materials, Inc.
Cision Canada
4 days ago
- Business
- Cision Canada
First Capital REIT Announces Date For Second Quarter 2025 Results Conference Call
TORONTO, June 25, 2025 /CNW/ - First Capital REIT ("First Capital") (TSX: invites you to attend the live conference call at 2:00 p.m. (ET) on Wednesday, July 30, 2025, with senior management to discuss financial results for the second quarter ended June 30, 2025. First Capital's financial statements and MD&A for the second quarter will be released prior to the call and will be available on its website at in the 'Investors' section, and on the Canadian Securities Administrators' website at Teleconference: You can attend the live conference call by dialing 416-340-2217 or toll-free 1-800-806-5484 with access code 5713675#. The call will be accessible for replay until August 6, 2025, by dialing 905-694-9451 or toll-free 1-800-408-3053 with access code 6977878#. Webcast: To access the live audio webcast and conference call presentation, please go to First Capital's website or click on the following link Q2 2025 Conference Call. The webcast will be accessible for replay in the 'Investors' section of the website. First Capital owns, operates and develops grocery-anchored, open-air centres in neighbourhoods with the strongest demographics in Canada.
Yahoo
4 days ago
- Business
- Yahoo
First Capital REIT Announces Date For Second Quarter 2025 Results Conference Call
TORONTO, June 25, 2025 /CNW/ - First Capital REIT ("First Capital") (TSX: invites you to attend the live conference call at 2:00 p.m. (ET) on Wednesday, July 30, 2025, with senior management to discuss financial results for the second quarter ended June 30, 2025. First Capital's financial statements and MD&A for the second quarter will be released prior to the call and will be available on its website at in the 'Investors' section, and on the Canadian Securities Administrators' website at Teleconference: You can attend the live conference call by dialing 416-340-2217 or toll-free 1-800-806-5484 with access code 5713675#. The call will be accessible for replay until August 6, 2025, by dialing 905-694-9451 or toll-free 1-800-408-3053 with access code 6977878#. Webcast: To access the live audio webcast and conference call presentation, please go to First Capital's website or click on the following link Q2 2025 Conference Call. The webcast will be accessible for replay in the 'Investors' section of the website. About First Capital REIT (TSX: First Capital owns, operates and develops grocery-anchored, open-air centres in neighbourhoods with the strongest demographics in Canada. TSX: SOURCE First Capital Real Estate Investment Trust View original content to download multimedia:
